Comparing the current results to its competitors, Aptevo Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 5.77 %, recorded in the same quarter.
Aptevo Therapeutics Inc , slower than the average decrease reported by the company's competitors of -60.26 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -60.26 %
Aptevo Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment with both U.S.-based and international producers of immune oncology products. Competitors developing antibody therapies targeting CD123 include Affimed, ImmunoGen, Innate Pharma/Sanofi, Macrogenics/Gilead, MD Andersen Cancer Center/Xencor, Menarini Group, Molecular Partners/University of Bern, Lava, and Sanofi. Other competitors developing non-CD123 antibody therapies include Cullinan, Novartis, Bio-Path, Shattuck Labs, Syros Pharma, Faron Pharma, and ALX Oncology. Additionally, gene and CAR-T therapies under development by various companies and institutions may compete with the company's mipletamig product.
For ALG.APV-527, which targets 4-1BB in a bispecific format cross-linked with tumor antigen 5T4, competition includes bispecifics targeting 5T4 and 4-1BB in preclinical development by Crescendo Biologics. Companies with 5T4-targeting drugs in clinical development include Biotecnol/Chiome Biosciences, which are developing 5T4 x CD3 bispecifics and various anti-drug conjugates (ADCs).
Competitors identified across company filings include Affimed, ALX Oncology, Bio-Path, Biotecnol, Chiome Biosciences, Crescendo Biologics, Cullinan, Faron Pharma, Gilead, ImmunoGen, Innate Pharma, Lava, Macrogenics, MD Andersen Cancer Center, Menarini Group, Molecular Partners, Novartis, Sanofi, Shattuck Labs, Syros Pharma, University of Bern, and Xencor.
Iterum Therapeutics Plc is a pharmaceutical company that focuses on the research, development, and commercialization of innovative anti-infectives for the treatment of serious and life-threatening infections. They aim to address unmet medical needs in this space by advancing their product candidates through clinical trials and ultimately bringing them to market.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Legend Biotech Corporation is a biotech company focused on developing innovative cell therapies and gene therapies to address unmet medical needs in various diseases.
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
Sources:
Aptevo Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aptevo Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
